Posted by Michael Wonder on 09 Mar 2023
Samsung Bioepis launches Lucentis biosimilar in Canada, Germany
5 March 2023 - According to industry sources on Sunday, SB11 was introduced to the Canadian market last Wednesday through its partner company Biogen, following an earlier launch in Germany on 23 February.
SB11 references Lucentis, a medicine developed by Genentech. It received sales approval in Europe and the US under the name Byooviz and in Korea as Ameliv.
